+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Cataract - Pipeline Review, H1 2015

  • ID: 3280643
  • Report
  • May 2015
  • 50 pages
  • Global Markets Direct
1 of 5
Cataract - Pipeline Review, H1 2015

Summary

This, ‘Cataract - Pipeline Review, H1 2015’, provides an overview of the Cataract’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cataract
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cataract
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Cataract Overview
Therapeutics Development
Pipeline Products for Cataract - Overview
Pipeline Products for Cataract - Comparative Analysis
Cataract - Therapeutics under Development by Companies
Cataract - Therapeutics under Investigation by Universities/Institutes
Cataract - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cataract - Products under Development by Companies
Cataract - Products under Investigation by Universities/Institutes
Cataract - Companies Involved in Therapeutics Development
CalAsia Pharmaceuticals, Inc.
EyeGate Pharmaceuticals, Inc.
InSite Vision Incorporated
Laboratorios Sophia S.A. de C.V.
Laila Pharmaceuticals Pvt. Ltd.
Omeros Corporation
R-Tech Ueno, Ltd.
Cataract - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bromfenac sodium + dexamethasone acetate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(sulfasalazine + Hyaluronic Acid) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-01309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRO-155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTU-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cataract - Recent Pipeline Updates
Cataract - Dormant Projects
Cataract - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cataract, H1 2015
Number of Products under Development for Cataract - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Cataract - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015
Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015
Cataract - Pipeline by InSite Vision Incorporated, H1 2015
Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2015
Cataract - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015
Cataract - Pipeline by Omeros Corporation, H1 2015
Cataract - Pipeline by R-Tech Ueno, Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cataract Therapeutics - Recent Pipeline Updates, H1 2015
Cataract - Dormant Projects, H1 2015
Cataract - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Cataract, H1 2015
Number of Products under Development for Cataract - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
- CalAsia Pharmaceuticals, Inc.
- EyeGate Pharmaceuticals, Inc.
- InSite Vision Incorporated
- Laboratorios Sophia S.A. de C.V.
- Laila Pharmaceuticals Pvt. Ltd.
- Omeros Corporation
- R-Tech Ueno, Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll